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SUMMARY
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This overview focuses on the (α,α-difluoromethylene)phosphonate mimic of phosphoserine
(pCF2Ser) and its application to the study of kinase-mediated signal transduction – pathways of great
interest to drug development. The most versatile modes of access to these chemical biological tools
are discussed, organized by method of PCF2-C bond. The pCF2-Ser mimic may be site-specifically
incorporated into peptides (SPPS) and proteins (expressed protein ligation). This isopolar, dianionic
pSer mimic results in a “constitutive phosphorylation” phenotype, and is seen to support native
protein-protein interactions that depend upon serine phosphorylation. Signal transduction pathways
studied with this chemical biological approach include the regulation of p53 tumor suppressor protein
activity, and of melatonin production. Given these successes, the future is bright for the use of such
“teflon phospho-amino acid mimics” to map kinase-based signaling pathways.

INTRODUCTION

NIH-PA Author Manuscript

It has long been known that biological macromolecules undergo kinase-mediated
phosphorylation. The reverse step, dephosphorylation, is also usually phosphatase-controlled.
Perhaps because the phosphorylation event itself greatly changes the charge distribution and
polarity of the substrate, it is often associated with signal transduction/amplification. This is
particularly the case for sequence-specific phosphorylations on the amino acid side chains of
serine, threonine and tyrosine. The bcr-abl kinase was the first of several to be successfully
targeted in a cancer therapeutic drug development, resulting in FDA approval of the drug
Gleevec (Imatinib) in 2001. As of this writing, no fewer than eight kinase inhibitors are on the
market for cancer chemotherapy (Boros and Boros, 2008; Pytel et al., 2009) and some 150
kinase inhibitors are in clinical trials (Savage and Gingrich, 2009). As such, the elucidation of
kinase/phosphatase-controlled signal transduction pathways has emerged as one of the most
important front end tasks in the medicinal chemistry arena.
Bioorganic chemists have long sought to develop functionalities that effectively mimic
biologically relevant phosphate esters, yet remain inert to phosphatase cleavage. This research
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domain resembles the peptidomimetics field, in that one seeks to build new organic functional
groups that retain key properties of the native structure, yet resist enzymatic bio-degradation.
Interestingly, organically bound fluorine has played an important role in both endeavors, surely
bolstered by polarity afforded by fluorine in compensating for lost oxygen atoms. For example,
fluoroalkenes, in which the electronegative fluorine atom replaces the carbonyl oxygen, can
serve as viable peptide isosteres (Welch, 2008). The strength of C-F bonds (O'Hagan, 2008),
and their ability to impose unique conformational constraints (Gorres et al., 2008; Nieschalk
et al., 1996) are important elements that support such designs. Moreover, the addition of
multiple C-F bonds can increase stability to chemical oxidation (DiMagno et al., 1996) and
metabolism, and provide additional driving force to enhance binding with macromolecular
targets, in aqueous solution (Biffinger et al., 2004).

NIH-PA Author Manuscript

Dating back to key early reports from the groups of Blackburn (Blackburn et al., 1981),
McKenna (McKenna and Shen, 1981) and Burton (Burton and Flynn, 1982) on pyrophosphate
mimics in the early 80's, there has emerged an interest in synthesizing α-fluorinated
phosphonates as potentially isopolar analogues (Blackburn et al., 1985b) of the corresponding
phosphate esters. This has spurred a great effort in methodology development in this area
(Benayoud et al., 1996; Blackburn et al., 1985a; Blackburn et al., 1994; Blades et al., 1997;
Caplan et al., 2000; Cockerill et al., 2000; Diab et al., 2008; Gautier et al., 2004; Herpin et al.,
1996; Hikishima et al., 2006; Lopin et al., 2003; Murano et al., 2005; Nair and Burton, 1997;
Ozouf et al., 2004; Pajkert et al., 2008; Pfund et al., 2005; Pignard et al., 2006; Roeschenthaler
et al., 2006; Xu et al., 2005; Yokomatsu et al., 2003). The phosphate mimics program in this
laboratory was initiated around the goal of establishing methods to access fluorinated
phosphonate analogues of sugar phosphates (Berkowitz et al., 2001; Berkowitz et al., 2000a;
Berkowitz et al., 1993; Shen et al., 1994), and continues in this direction, with a particular
interest, of late, in bivalent sugar phosphonates as ligands for the mannose 6-phosphate-insulinlike growth factor II receptor (M6P/IGF2R) (Berkowitz et al., 2004; Fei et al., 2008).
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While phosphorylations at threonine (Di Croce and Shiekhattar, 2008; Kulasekara and Miller,
2007), and certainly tyrosine (Franco and Tamagnone, 2008; Girault, 2006; Grangeasse et al.,
2007; Nag and Chaudhary, 2009; Roskoski, 2008; Zhang et al., 2009), are of great importance,
this overview focuses on serine phosphorylation (For nice complementary discussions from
the groups of Otaka and Ojea, primarily focusing on the chemistry of other phosphono-AA's
see: (Fernandez et al., 2006; Otaka et al., 2000; Otaka et al., 2004)). More specifically, we will
examine the use of the (α,α-difluoromethylene)phosphonate functionality to mimic the
phosphate monoester form of serine residues, in proteins that are subject to regulation via serine
phosphorylation. The archetypical example of such a system is represented by the complex
interplay of the enzymes glycogen phosphorylase (GP - catabolism), and glycogen synthase
(GS - anabolism) cascades associated with glycogen metabolism. These enzymes are each
tightly controlled via kinase/phosphatase enzymes that respond to hormonal signals from
epinephrine or insulin. For example, epinephrine binding to its cognate receptor results in the
activation of adenylate cyclase (Sunahara et al., 1996), and the formation of cAMP, the
“universal second messenger.” This leads to the activation of cAMP-dependent protein kinase
A, which, in turn, activates phosphorylase kinase, which itself activates glycogen
phosphorylase, both activations occuring via enzymatic phosphorylations at serine residues
(Toole and Cohen, 2007).
It now appears that the principal phosphorylations are at Ser-14 in GP and at Ser-7 and Ser-640
in GS (Toole and Cohen, 2007). However, the complexity of kinase-phosphatase regulation of
this key metabolic branch point is remarkable. For example, in GS alone, nine serine residues
can be phosphorylated by regulatory kinases, leading to a theoretical complexity of 512
combinations of distinct Ser/pSer patterns, each potentially with a different kinetic profile.
Fortunately, due to hierarchal phosphorylation, the number of configurations of GS observed
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is considerably lower. The group of Jensen has painstakingly set about to identify and
kinetically characterize the most important “phospho-forms” of this enzyme (Jensen and Lai,
2009).
Synthesis of the pCF2-Ser Phosphoserine Mimic
It occurred to us and others that for the study of such signal transduction pathways, it would
be useful to have available a stable mimic of the phosphorylated form of the enzyme. Indeed,
this led us to develop the first synthesis of the CF2-phosphonate mimic of pSer, in a form
suitable for automated peptide synthesis, 15 years ago. Actually, both our first generation, and
our second generation synthesis, starting from L-serine, and (R)-isopropylideneglycerol,
respectively, were disclosed in that first communication (Schemes 1 and 2) (Berkowitz et al.,
1994b). In the following year, the groups of Otaka and Burke collaboratively reported a
complementary approach to the same target (Otaka et al., 1995a). In what follows, these
syntheses are organized according to PCF2-C bond disconnection, and they are presented along
with several more recent approaches, to provide the medicinal chemist with an overview of
the routes available to synthesize this “teflon pSer mimic.” This is followed by a look at elegant
studies, by the groups of Appella and Cole, respectively, on using this pSer mimic to examine
the role of serine phosphorylation in signal transduction.
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In Scheme 1 is presented our first generation approach to the pCF2-Ser building block for
peptide synthesis. A chiron approach was taken, emanating from L-serine. As alluded to earlier,
an important observation had been made in our lab that informed our thinking about (α,αdifluoromethylene)phosphonate synthesis. Namely, in early work by Blackburn and
coworkers, it was observed that the LiCF2P(O)(OEt)2 anion is unstable to α-elimination to
difluorocarbene, at temperatures of approximately −40 °C or higher (Bla ckburn et al., 1987).
Therefore, we sought to develop especially efficient ways of capturing this nucleophile, at low
T. Indeed, it was found that displacements of primary sugar triflates generally proceed at −78
°C with this rea gent, in a matter of minutes (Berkowitz et al., 1993). This behavior contrasted
sharply with the markedly lower reactivity of alkyl halides.
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In seeking to apply the triflate displacement approach to the synthesis of the pSer mimic, we
were confronted with an issue of functional group cross-compatibility. Namely, would it be
possible to carry a masked amino group into the triflate scaffold itself, so that the synthesis
could commence with L-serine itself? In fact, the challenge was much greater. Because of the
densely functionalized serine framework, the desired pCF2-Ser synthon was to possess an αtriflyloxy, (protected)-β-amino substructure (Scheme 1). It was found that mono-protection of
the amine, even with strongly electron-withdrawing N-sulfonyl functionality, did not lead to
manageable triflates, perhaps due to neighboring group participation (possible aziridinium ion
formation). Thus, bis-protection of the neighboring nitrogen, (i) as an acyclic Bn-N-Ts group,
(ii) through incorporation into a 2,5-dimethylpyrrole group, or (iii) through cyclization to the
oxazolidinone (as in Scheme 2), and N-benzylation, all led to primary triflates that were stable
to chromatography, and could be displaced by LiCF2P(O)(OEt)2. However, in all cases, Ndeprotection, in the presence of the resultant fluorinated phosphonate, proved problematic. A
solution was found with the latter protection scheme, wherein the N-benzyl protecting group
was replaced with a much more labile N-TBS blocking group.
The N-protecting group problem that emerged in this first generation route resulted in a longer
synthesis than envisioned, that also suffered from suboptimal N-deprotection conditions.
Namely, introduction of the N-BOC functionality serves the dual purpose of activating the
oxazolidinone for ring opening, and installing a protecting group appropriate for peptide
synthesis. Unfortunately, that ring opening proceeds in modest yield and limits the efficiency
of this route. So, the phosphonate team in the lab set about on a parallel route, in which triflate
displacement would still be employed for fluorinated phosphonate installation, but upon a
Chem Biol. Author manuscript; available in PMC 2010 September 25.
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glyceryl acetonide scaffold, rather similar to the sugar scaffolds originally employed
(Berkowitz et al., 1993). This worked smoothly and allowed for late introduction of nitrogen,
via azide displacement upon a secondary triflate (Scheme 2). This remains a rather streamlined
and underused route into the pCF2-Ser target. Chemical biologists active in this field are
encouraged to examine this isopropylidineglycerol route, if in need of a clean rapid entry into
this phosphono-peptide building block.

NIH-PA Author Manuscript

Indeed, highlighting the practicality of this type of approach, the efforts of a phosphonate group
in Tokyo, under Shibuya (Yokomatsu et al., 1996), resulted in a conceptually different
approach to stereocontrol, while retaining the same sort of triflate displacement chemistry as
had been employed in our second generation synthesis (Scheme 3). Cleverly, Yokomatsu et
al. utilized the monoacetonide of the C3v-symmetrical tris(hydroxymethyl)methane (THYM)
starting material as triflate precursor. Triflate displacement proceeds smoothly. This is
followed by acetonide cleavage to produce a 1,3-diol that may be efficiently desymmetrized
with several lipases. Note that enzymatic desymmetrization is, of course, an excellent strategy
for achieving both high ee and high throughput. The strategy is exceedingly efficient here, and,
in our own experience, can be employed with advanced meso intermediates (Berkowitz et al.,
2000b; Berkowitz et al., 1996b), relatively deep into total synthetic ventures, particularly with
lipase enzymes. Secondly, we have also found that, lipase-mediated hydroxymethyl arm
acylation, is a very effective strategy for chiral discrimination for unnatural amino acids. This
approach works, even for quaternary amino acid synthons, after reduction of the α-carboxyl to
a hydroxymethyl group (Berkowitz et al., 1994a).
Also in this case, N-introduction occurs late in the synthesis, but via Curtius rearrangement,
instead of triflate displacement. The Tokyo route and our second generation triflate
displacement route also share the advantage of permitting N-carbamate deprotection, in situ,
though in different ways. Interestingly, since the original Shibuya route was published, studies
by Guanti and coworkers (Banfi and Guanti, 1998; Banfi et al., 2005), in particular, have
produced a number of methods for tris(hydroxymethyl)methane desymmetrization. So, one
should be able to enter this triflate displacement route with a single antipode of this type of
THYM educt. The resulting phosphonate would possess differentially protected
hydroxymethyl arms, streamlining the Tokyo route even further.

NIH-PA Author Manuscript

All of the aforementioned triflate displacement-based chemistry was carried with diethyl
protection across the fluorinated phosphonate moiety, as this is the most well studied synthon.
It is worthy of note that we have developed complementary fluorinated phosphonate reagents,
carrying both dibenzyl (Berkowitz et al., 1999) and diallyl (Berkowitz and Sloss, 1995)
phosphonate protection. Both reagents have performed well in model triflate displacement
studies, and may, in the future, allow for adaptation of these routes to the synthesis of pCF2Ser monomers bearing more convenient side chain protecting groups.
Scheme 4 highlights a route developed jointly by Kawamoto and Campbell (Kawamoto and
Campbell, 1997) that features transition metal-mediated alkene addition of (RO)2P(O)
CH2ZnBr, similar to a reaction developed by Burton, under both Pd and Cu-catalysis (Yang
and Burton, 1992). Related transformations have been developed in the thiono series by Piettre
and colleagues, more recently (Lequeux et al., 2001;Pignard et al., 2006). These latter reactions
do not require transition metal catalysis, and are routinely run under radical chain conditions.
Following (RO)2P(O)CF2-radical addition to α-bromoacrylate, nitrogen is introduced late via
bromide displacement. Stereocontrol comes still later, through a classical resolution, via
chromatographic separation of the diastereomeric bornyl esters.
Lastly, the original Otaka route (Scheme 5) features a third method of fashioning the PCF2-C
linkage, namely via (RO)2P(O)CF2Li addition to carbonyl centers (Otaka et al., 1995a;Otaka
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et al., 1995b). Specifically, the Kyoto group utilizes the Garner aldehyde (Garner and Park,
1992), and employs a carbonyl addition/Barton ester-type deoxygenation sequence, similar to
that described by Martin and coworkers, in non-AA contexts (Martin et al., 1992). Our own
carbonyl addition route (Berkowitz et al., 1996a), utilizes the Garner ester as electrophile and,
by design, allows the experimentalist to assess three different L-(α,α-difluoromethylene)
phosphono AA's, the analogues of pSer, p-allo-Thr and pThr, from a common, β-keto-α,αdifluorophosphonate intermediate, by treatment either with LiBH4 or with MeMgBr, prior to
deoxygenation. As can be seen (Scheme 5), if one only wishes to synthesize the pCF2-Ser
mimic the two routes are very similar (Corey-Schmidt (PDC-DMF) oxidation vs. RuO4 in final
step). Because of the ready accessibility of the Garner ester, this route appears to be the most
widely used. The fact that it also provides access to the individual L-phosphonothreonine
diastereomers makes this a versatile approach.
Use of the pCF2-Ser Mimic as a Tool for the Study of Signal Transduction

NIH-PA Author Manuscript

The p53 protein is a tightly regulated tumor suppressor protein (Sherr, 2004), mutated in 50%
of human cancers (Bykov et al., 2002; Toledo and Wahl, 2006). The p53 protein, when
activated, dissociates from its mdm2 (hdm2 is the human equivalent) binding partner,
undergoes conformational change, and acts as a transcription factor, typically leading to either
cell cycle arrest or apoptosis (Liebermann et al., 2007). Both appear to be protection
mechanisms, especially with the finding that tumor senescence may be associated with
inflammatory cytokine up-regulation and tumor clearance (Xue et al., 2007). Activation of p53
occurs in response to cellular stress signals, including DNA damage, osmotic shock (Kishi et
al., 2001), oxidative stress (Han et al., 2008) and hyperglycemia. Conversion of the latent form
of p53 to its active transcription factor form appears to involve initial phosphorylation
(primarily at N-terminal serines) and subsequent acetylation (C-terminal lysines- K320 and
K382).
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Several experiments underscore the importance of understanding p53 function and regulation,
especially for medicinal chemistry programs in the oncology (Bell and Ryan, 2007; Haupt and
Haupt, 2006; Vassilev, 2005), and diabetes areas (Fiordaliso et al., 2001). Jacks and coworkers
developed a clever genetic construct for temporal control of p53 expression (Ventura et al.,
2007). Initially, p53 was held genetically latent, and could be restored via a Cre recombinase
mechanism. Restoration of p53 function was shown to lead to tumor regression, with the effect
dependent on tumor type. This work pointed to the importance of altered p53 function in
tumorigenesis and tumor maintenance. This genetic system, then, serves as a model for
pharmacological reactivation of p53. Indeed, along those lines, a couple of interesting early
small molecule modulation experiments have come to the fore. For example, small molecules
capable of both restoring transcriptional activation function to p53 mutants (Bykov et al.,
2002), and capable of inhibiting p53-mdm2 interactions (Vassilev et al., 2004) have been
described, each avenue representing a fundamentally new approach to cancer chemotherapy,
if viable.
Given the prevalence of p53 abnormalities in cancer, and the importance of serine
phosphorylation in its regulation, there has been a very high level of interest in the study of
kinase-regulated signal transduction in this system. Among the candidate sites for p53
modulation, via phosphorylation, are included S-6, S-9, S-15, T-18, S-20, S-33, S-37, S-46, at
the N-terminus, as well as S-315 and S-392, at the C-terminus. In terms of regulatory
complexity, at the level of serine phosphorylation, this system, then, is reminiscent of the
glycogen phosphorylase/glycogen synthase pair discussed earlier. Interestingly, at the Cterminus of p53, O-glycosylation may be in direct competition with O-phosphorylation (Clarke
et al., 2008; Haltiwanger et al., 1997; Hart et al., 1995; Wells et al., 2003), with the former
being particularly important in cases of hyperglycemia (Fiordaliso et al., 2001).
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From a chemical biology point of view, one way of examining the effect(s) of post-translational
modifications, is to engineer functional variants that model both the “switched “on” and
“switched off” states of the macromolecule. While it is easy to genetically engineer
“constitutively dephosphorylated” sites by mutating phosphorylation site Ser residues to Ala
residues, and this has been shown to be quite effective in the p53 system (Yamauchi et al.,
2004), the reverse mutation is unavailable by standard molecular biological techniques, as Asp
or Glu are often unsuitable mimics of pSer (Zheng et al., 2003), and there are no better choices
available among the proteinogenic AA's. The incorporation of a phosphatase-inert pSer mimic,
position-specifically, into a protein of interest, is now possible with expressed protein ligation
(EPL) techniques. Moreover, in such endeavors, it appears to be especially advantageous to
use phosphono-AA mimics in which a CF2 (as opposed to a CH2) replaces the bridging ester
oxygen (Zhang et al., 2003). Among the possible reasons for this advantage, is the
aforementioned “isopolarity” of the CF2 unit with the native bridging O. However, pKa effects
may be even more important. The simple CH2-phosphono analogue of pSer is expected to have
pKa2 of 7-8, whereas its CF2-phosphono counterpart typically displays pKa2 under 6,
depending upon molecular context (Berkowitz and Bose, 2001; Berkowitz et al., 2000a;
Blackburn et al., 1984). Thus both the native pSer residue and the pCF2-Ser mimic will present
as almost exclusively dianionic side chain modifications under most conditions. This ability
to bring in such a chemically tuned, hydrolytically stable, pSer mimic, using EPL techniques,
will be discussed below, in the context of recent studies of melatonin regulation.

NIH-PA Author Manuscript

In the p53 area, the most common modus operandi for studying site-specific phosphorylation
itself, i.e, for running “phosphorylation-positive” experiments, is a reactive one, rather than a
pro-active one. That is to say, rather than effectively generate “constitutive” pSer sites in p53
and examine functional responses to these, one looks at the pSer profile of p53 in response to
a stimulus. The analytical tools needed for such studies are a set of antibodies (Ab's) for sitespecific phosphorylation variants of p53. For p53, activation usually involves serine
phosphorylation, with sites available at both the N- and C-terminal regions.
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A precedent-setting study in antibody-based mapping technology was carried out by Appella
and coworkers at the NIH (Higashimoto et al., 2001; Higashimoto et al., 2000) (Scheme 6).
The group sought to specifically examine phosphorylation at Ser-6 and Ser-9 in p53, in
response to DNA damage. It was found that one could successfully raise Ab's against pSer-9containing peptide-KLH-protein conjugate, and that these Ab's, in turn, effectively recognized
p53 protein that was specifically phosphorylated at Ser-9. However, the same procedure for
producing pSer-6-complementary Ab's failed. Ab's were obtained, but these recognized only
p53 samples presenting an unphosphorylated Ser-6-site. It appears that the peptidyl-KLH
conjugate suffered phosphatase-mediated Ser-6-O-phosphate cleavage in the rabbit
immunization step.
Appella's team astutely recognized that the use of an “isosteric and isopolar,” (Blackburn et
al., 1985b; Blackburn et al., 1981) yet hydrolytically stable, pSer mimic might overcome this,
otherwise apparently insurmountable, barrier. As is depicted in the scheme, the pCF2-Ser
mimic, indeed, served this purpose exceptionally well, producing high titres of Ab that
recognized only pSer-6-post-translationally modified (PTM) p53 samples. This experiment
demonstrates, at once, the utility of this phosphoserine mimic for overcoming phosphatase
cleavage, and its ability to quite accurately mimic the size, polarity and charge distribution of
the native PTM. After all, the raised Ab was “remodeled” against the pSer surrogate, and
deployed against actual, pSer-modified p53, and showed complete fidelity in recognizing the
true functionality.
Using this chemical biological tool, the Appella group was able to establish that Ser-6 is
phosphorylated in response to DNA damage induced by both UV light and ionizing radiation
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(Higashimoto et al., 2000). In subsequent studies, an unexpected interdependence was seen
between Ser-6 and Ser-9 phosphorylation (Saito et al., 2003). That is, in the absence of Ser-9
(S9A mutant), no phosphorylation is seen at Ser-6, and vice versa. This work established that
the N-terminal transactivation domain of p53 appears to be divisible into four clusters of
interdependent serine residues, from the point of view of phosphorylation. This site
interdependency model is seen as a mechanism for both control and signal amplification.
As alluded to in the previous discussion, it would be even more powerful if one could generate
phosphorylation “knock-in” mutants to complement the phosphorylation “knock-out” mutants
typically constructed by Ser to Ala mutations. This would allow one to go beyond analyzing
phosphorylation patterns that are generated by native kinases. Rather, one would be generating
artificially a “constitutive phosphorylation signal” and examining the downstream
consequences of that signal transduction event.
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In Scheme 7 is illustrated a seminal study by the group of Philip Cole at Johns Hopkins, that
uses the power of EPL to surgically insert the pCF2-Ser mimic of pSer into a protein, at a site
of interest (Zheng et al., 2005). The EPL technique (Muir et al., 1998;Schwarzer and Cole,
2005) involves coupling intein technology to cysteine ligation methodology inherent in the
parent native chemical ligation procedure (Dawson et al., 1994). EPL may be regarded as the
state of the art for chemical biological manipulation of side chain functionality, and is especially
useful for studying PTM's and their relation to signal transduction (Flavell and Muir,
2009;Pickin et al., 2008;Rauh and Waldmann, 2007).
In the case at hand, Cole and co-workers were interested in examining closely the regulation
of arylalkylamine N-acetyltransferase (AANAT), and enzyme that catalyzes the penultimate
step in the biosynthesis of the time-keeping hormone, melatonin (Klein, 2007). Melatonin, Nacetyl-5′-methoxytryptamine, is biosynthesized by the decarboxylation of 5′hydroxytryptophan to serotonin, followed by N-acylation and O-methylation. It is the Nacylation step that is mediated by AANAT, with acetyl-CoA serving as acyl donor. It had been
surmised that phosphorylation at Thr-31, and potentially Ser-205, modulated in vivo
acyltransferase activity. Two mechanisms for this effect were in play: (i) improving the
catalytic efficiency for the acyl transfer reaction and (ii) increasing the biological half-life of
AANAT enzyme.
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The mechanism for AANAT stabilization is an interesting one, namely the protein is thought
to be shielded from proteosomal proteolysis by association with a specific14-3-3 adaptor
protein; namely the zeta-variant. Over 100 signaling proteins have been reported to bind to
14-3-3 proteins, and these interactions are typically associated with pSer or pThr modifications
on the signaling protein (Klein et al., 2003; Obsil et al., 2001; Tzivion and Avruch, 2002). In
the case at hand, in the dark, AANAT activity and protein levels increase. The putative
activating phosphorylation(s) are thought to be mediated by protein kinase A, in response to
elevated cAMP levels, in the pineal gland, as a result of a1 or b-adrenergic receptor activation.
Thus, through EPL with the title pSer mimic, the Cole group sought to engineer in “constitutive
phosphorylation” at position-205, and test for positive interaction between AANAT and its
14-3-3-zeta partner.
In the Hopkins experiment, the requisite octapeptide for EPL was synthesized by standard solid
phase peptide synthesis (SPPS). The sequence represents a modified C-terminus, in that the
Ser residue normally at position 205 was replaced by the pCF2-Ser mimic, and a Cys residue
was installed in place of the native Ala-200, to enable the cysteine-mediated acyl transfer
chemistry that underlies the ligation chemistry in EPL. On the other end, the AANAT protein
itself was expressed as a complementary C-terminal (8-) truncated-intein-CBD (chitin binding
domain) fusion construct. The CBD domain allowed for facile purification via affinity
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chromatography. The tag could then be clipped by transthio-esterification with βmercaptoethanesulfonate, setting the stage for ligation. Incubation of the synthetic, N-Cysterminated, (α,α,-difluoromethylene)phosphono-peptide proceeded cleanly, presumably via
the usual two stage, intermolecular trans-thio-esterification/intramolecular S-N acyl transfer
mechanism, providing the targeted semi-synthetic protein (Scheme 7).
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Using this construct, the Cole group was able to demonstrate clearly that Ser-205
phosphorylation, though at the C-terminus and not a part of a recognized 14-3-3-zeta consensus
sequence, enhances cellular stability of the AANAT protein. Subsequent studies showed that
this effect persists in live cells, expanding the domain in which such “teflon phosphates” may
be deployed to ask fundamental questions in chemical biology (Szewczuk et al., 2008).
Interestingly, from this latter study, it was confirmed that, surprisingly, Ser-205
phosphorylation on AANAT confers a greater binding affinity for 14-3-3-zeta (0.86 μM Kd)
than does Thr-31 phosphorylation (1.8 μM Kd). On the other hand, the latter PTM alone
improves the catalytic efficiency (kcat/Km) of the acyl transferase by approximately 7-fold,
largely by decreasing the Km for serotonin. However, that catalytic improvement is essentially
lost when both modifications are present. These observations, when taken together are
consistent with a two point (N-terminal pThr and C-terminal pSer) binding model for the
interactions between AANAT and its 14-3-3-zeta partner. So, in the end, both mechanisms
postulated for increased AANAT activity, improved catalytic efficiency (seen with sole
pThr-31 modification), and increased stability to proteolysis through binding to 14-3-3-zeta
(seen with sole pSer-205 phosphorylation and with pThr-31/pSer-205 dual phosphorylation)
appear to be operative.

CONCLUSIONS
The (α,α-difluoro)methylene phosphonate analogue of L-phosphoserine is available through
chemistry employing a M-CF2P(O)(OR)2 equivalent for PCF2-C bond formation via: (i) triflate
displacement; (ii) carbonyl addition/reduction or (iii) Cu-mediated alkene addition. Within
these approaches, absolute stereochemistry is controlled by (i) starting from an appropriate
chiral synthon - L-serine, D-serine or (R)-isopropylideneglycerol; (ii) utilizing a chiral catalyst
(lipase P) to desymmetrize an achiral intermediate or (iii) attaching a covalent chiral auxiliary
for enantiomer resolution. The pCF2-Ser mimic may be incorporated into peptides utilizing
SPPS, either for purposes of raising antibodies to specific pSer modifications, or for installation
a “constitutive pCF2-Ser modification” into the native protein itself, using EPL methods. The
former application was used to firmly establish a connection between p53 Ser-6
phosphorylation and DNA damage, and the latter clarified the role of Ser-205 phosphorylation
of AANAT enzyme stabilization.

NIH-PA Author Manuscript

This technology adds an important element into the toolbox available to the chemical biologist
interested in studying signal transduction. Fundamental mechanistic questions relating to
kinase-mediated signal transduction in tumor suppression, and in diurnal regulation of the timekeeping hormone, melatonin, have been addressed. As the aforementioned studies
demonstrate, fluorinated phosphonate analogues of phospho-amino acids provide for
metabolically stable alternatives to the native phospho-proteins, while retaining the ability to
promote protein-protein interactions that depend on that phosphorylation. This makes these
unnatural amino acid analogues invaluable tools for the dissection of such signal transduction
pathways. With the maturation of semi-synthetic hapten construction, expressed protein
ligation and unnatural amino acid mutagenesis (Liu and Schultz, 1999; Xie and Schultz,
2005, 2006), and the importance of kinase-mapping in the present day, the time is ripe for
expanded use of this isopolar phosphoserine mimic in chemical biology.
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Scheme 1.

PCF2-C Bond Formation via Triflate Displacement – Stereocontrol via Chiron Approach from
L-Serine
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Scheme 2.

PCF2-C Bond Formation via Triflate Displacement – Chiron Approach from (R)Isopropylidene-glycerol
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Scheme 3.

Shibuya Route: PCF2-C Bond Formation via Triflate Displacement – Enzymatic
Desymmetrization
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Scheme 4.

Kawamoto-Campbell-Burton Route: PCF2-C Bond Formation via Cu-Mediated Resolution of
Borneol Esters
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Scheme 5.

Berkowitz-Otaka Route: PCF2-C Bond Formation via Carbonyl Add'n – Chiron Approach
from D-Serine
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Scheme 6.

Use of the pCF2-Ser Mimic to Study of Position-Specific Phosphorylation of p53 in Response
to DNA Damage - Appella
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Scheme 7.

Use of the pCF2-Ser Mimic to Study the Effects of Position-Specific Phosphorylation of
AANAT on the Melatonin Cycle - Cole
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